Genelife Clinical Research Pvt. Ltd.

Medical device clinical research has evolved dramatically over the past fifteen years — but many of the fundamental design challenges remain unchanged.

In this perspective article, we revisit the core questions first explored in 2011 and examine how adaptive trials, Bayesian methods, real-world evidence (RWE), EU MDR, digital integration, and decentralized models are reshaping modern medical device clinical trials.

The article explores:

• Why device trials differ fundamentally from pharmaceutical studies

• How platform and adaptive designs are improving evidence generation

• The growing regulatory role of real-world evidence

• The impact of EU MDR on clinical evidence expectations

• How digital technologies are transforming what can be measured in clinical research

🩸 World Blood Donor Day 2026

Every blood donation is a gift of life, hope, and humanity. On this World Blood Donor Day, we express our heartfelt gratitude to all voluntary blood donors whose selfless contributions save millions of lives every year.

At Genelife Clinical Research, we recognize the importance of healthcare initiatives that strengthen patient care and improve lives globally. Let us continue to encourage awareness, compassion, and community participation in blood donation.

❤️ Donate blood. Save lives. Inspire hope.

India's biosimilar regulatory framework has changed more in the last decade than most development teams realize.

On Monday we published a detailed guide for international nutraceutical companies conducting clinical studies in India.

The question we hear most from international sponsors considering India for the first time:

"Will the data actually be accepted by our regulator?"

The answer is yes — but the conditions matter more than most sponsors realize before they start.

The FDA, EMA, TGA, and Health Canada all accept clinical data generated in India, provided the study was conducted under ICH GCP, the design meets the target market's evidentiary requirements, bioanalytical methods are validated to the appropriate standard, and the clinical study report is written to ICH E3 guidelines.

None of those conditions are difficult to meet. But all of them require a CRO partner that knows what international regulatory acceptability actually means in practice — not just a partner that is good at conducting studies for the domestic Indian market.

The gap between those two things is wider than most international sponsors expect. And discovering it after the study is complete is an expensive way to find out.

International nutraceutical sponsors ask us one question more than any other:

"Will data from an Indian study be accepted by FDA / EMA / TGA?"

Yes. If:

→ The study is conducted under ICH GCP → The design meets your target market's evidentiary standard → Bioanalytical methods are validated to FDA/EMA guidelines → The clinical study report meets ICH E3 requirements → Your CRO partner understands international regulatory submissions — not just Indian ones

That last point is where most India-based studies for international sponsors fall short.

Reposting:

The EU rejected most botanical health claims submitted for authorization. The FTC is scrutinizing supplement claims with increasing aggression. The TGA is tightening listed medicine evidence requirements.

The global regulatory direction for nutraceuticals is clear: prove it clinically, or lose the claim.

The problem: clinical trials in the US and EU are expensive enough that the ROI is genuinely difficult.

The solution more international nutraceutical companies are finding: conduct the study in India.

80% of clinical trials fail to meet enrollment timelines.

The molecule is rarely the problem. The patients are.

In our latest article, we examine why recruitment failures are almost always predictable — built into protocol design, site selection, and planning decisions made months before the first patient is screened.

Most clinical trials don't fail because the science was wrong.

They fail because:

→ Sites weren't activated on time

→ Enrollment targets were optimistic, not evidence-based

→ Data issues were caught late

→ No one owned the full picture

Regulators in the US, EU, Australia, and UK are all moving in the same direction on nutraceutical health claims.

The era of marketing on plausibility and tradition alone is ending. Clinical evidence — rigorous, human, controlled — is becoming the price of credible market positioning.

The question for international nutraceutical companies isn't whether to generate that evidence. It's how to do it at a cost and speed that makes commercial sense.

That's where India comes in.

The same randomized controlled trial that costs USD 1–2 million in the US or Western Europe can be conducted in India — to the same ICH GCP standards, generating data acceptable to FDA, EMA, and TGA — at 30 to 50 percent of that cost. With faster ethics approvals, faster recruitment, and a patient population that is uniquely relevant for metabolic, inflammatory, and nutritional intervention studies.

The companies that are ahead of the regulatory curve are already doing this.

In 2012, we wrote about the challenges of drug–device combination products.

We just revisited that article — 13 years later.

What's the same: → The benefits still justify the complexity → Two-facility manufacturing is still the right model

What's completely different: → Cybersecurity is now a regulatory requirement → Human factors studies are mandatory → Digital integration has created an entirely new category of challenge → Post-market surveillance expectations have expanded dramatically

The conclusion then: the benefits justify the complexity. The manufacturing model that made most sense: two distinct facilities, coordinated but separate.

Thirteen years later, we've revisited that article — and the verdict is the same. But almost everything around it has changed.

In 2012, the products were stents, inhalers, prefilled syringes. Today, they include wearable injectors, connected inhalers with real-time adherence tracking, and implantable delivery systems with remote monitoring.

In 2012, cybersecurity was not a consideration. Today, it is a lifecycle regulatory requirement for any digitally integrated device.

In 2012, human factors engineering was a best practice. Today, it is mandatory — and regulators expect structured usability studies that prove patients can use the product correctly in real-world conditions.

The complexity has grown significantly. So has the clinical impact and the commercial opportunity.

Our updated perspective — what's changed, what hasn't, and what it means for your program — is now on the blog.

#DrugDeviceCombination #CombinationProducts #MedicalDevices #ClinicalResearch #RegulatoryStrategy #Pharma #DigitalHealth



We published an article on Monday about post-marketing surveillance for biosimilars.

Here's the point that matters most for anyone in this space:

Regulatory approval of a biosimilar is built on a deliberately limited clinical dataset.

That's not a flaw in the system — it's the logic of the abbreviated development pathway. Comparability data reduces the pre-approval burden. Post-marketing surveillance carries the rest.

Which means pharmacovigilance isn't a compliance obligation you manage after launch. It's the second half of your evidence strategy.

The organizations that treat it that way — investing in robust immunogenicity monitoring, structured Phase IV studies, and real-world evidence generation from day one — build market trust that approval alone never could.

The ones that don't find out the hard way that a missed signal or a traceability gap costs far more than the infrastructure they chose not to build.

Biosimilar approval is not the finish line.

It's the point at which your pre-approval dataset — intentionally smaller than a novel biologic — meets real patients, real clinical practice, and real immune systems.

What happens next depends entirely on your post-marketing infrastructure:

→ Are you detecting immunogenicity signals before they become safety events? → Is your traceability good enough to link adverse events to the right product? → Are your Phase IV studies generating data that builds prescriber confidence?

Reposting one of our key insights on selecting the right CRO partner for clinical research programs.

Choosing a CRO is not only about operational support — it directly impacts study timelines, regulatory compliance, data quality, and overall trial success.

India's biosimilar regulatory framework has changed more in the last decade than most development teams realize.

Phase III trials — once mandatory — can now be waived under the right scientific conditions. Indication extrapolation is now explicitly permitted. Animal studies are no longer routine. And analytical similarity has moved from a supporting role to the foundation of the entire development strategy.

These are not minor procedural updates. They are structural changes to how a biosimilar program should be designed — and they have direct implications for timelines, costs, and the scope of your commercial opportunity.

We are reposting the article again, in case you missed that: